Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Sep 23.

Published in final edited form as: J Allergy Clin Immunol. 2013 Jul 16;132(5):1086–1096.e5. doi: 10.1016/j.jaci.2013.05.020

FIG 2 — Airway eosinophils (/mm²) for individual subjects (ATP population).

a) Cohort 1 IV: placebo, n = 5; benralizumab 1 mg/kg, n = 8.

b) Cohort 2 SC: placebo, n = 5; benralizumab 100 mg, n = 4; benralizumab 200 mg, n = 5. Dashed lines represent upper limit of normal (ULN) for airway eosinophil counts (22/mm²).^4,15

c) Cohort 2 SC. Representative immunofluorescence photomicrographs showing mucosal and submucosal tissue sections obtained from one placebo subject and one benralizumab subject at screening and day 84. Green indicates anti-major basic protein-1-stained eosinophils and blue indicates 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei. The inserts show sections at x400 magnification.

FIG 2 — Airway eosinophils (/mm²) for individual subjects (ATP population).

a) Cohort 1 IV: placebo, n = 5; benralizumab 1 mg/kg, n = 8.

b) Cohort 2 SC: placebo, n = 5; benralizumab 100 mg, n = 4; benralizumab 200 mg, n = 5. Dashed lines represent upper limit of normal (ULN) for airway eosinophil counts (22/mm²).^4,15

c) Cohort 2 SC. Representative immunofluorescence photomicrographs showing mucosal and submucosal tissue sections obtained from one placebo subject and one benralizumab subject at screening and day 84. Green indicates anti-major basic protein-1-stained eosinophils and blue indicates 4′,6-diamidino-2-phenylindole (DAPI)-stained nuclei. The inserts show sections at x400 magnification.